See every side of every news story
Published loading...Updated

Pfizer to seek approval for RSV vaccine for people as young as 18

  • Pfizer's RSV vaccine, Abrysvo, demonstrated a strong immune response in adults aged 18 to 59, protecting against RSV-associated illness.
  • The vaccine trial included adults with underlying chronic conditions like asthma and diabetes, who are at higher risk of RSV.
  • Hawaii Department of Health is investigating cases of pertussis, a highly contagious respiratory illness causing severe coughing fits and other complications.
Insights by Ground AI
Does this summary seem wrong?

73 Articles

All
Left
10
Center
29
Right
9
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources are Center
60% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Science News broke the news in United States on Tuesday, April 9, 2024.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.